Hosted on MSN15d
Akero Therapeutics director Graham Walmsley acquires $9.6 million in stock
Walmsley, a director at Akero Therapeutics ... The shares are primarily held through Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where Walmsley is a managing member of the ...
Reuters27d
Akero soars as drug shows it reverses scarring in liver disease patients
Jan 27 (Reuters) - Akero Therapeutics (AKRO.O), opens new tab shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse ...
Business Insider27d
Akero Therapeutics MASH data ‘best-case-scenario,’ says Citi
Citi analyst Jonathan Woo says Akero Therapeutics (AKRO)’ 96-week data update from its SYMMETRY trial of efruxifermin for patients with compensated cirrhosis due to metabolic dysfunction ...